Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America

BACKGROUND: Since April 2016 inactivated poliovirus vaccine (IPV) has been the only routine source of polio type 2 protection worldwide. With IPV supply constraints, data on comparability of immunogenicity and safety will be important to optimally utilize available supplies from different manufactur...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Medina, Eduardo, Melgar, Mario, Gaensbauer, James T., Bandyopadhyay, Ananda S., Borate, Bhavesh R., Weldon, William C., Rüttimann, Ricardo, Ward, Joel, Clemens, Ralf, Asturias, Edwin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464088/
https://www.ncbi.nlm.nih.gov/pubmed/28455172
http://dx.doi.org/10.1016/j.vaccine.2017.04.041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464088/
https://www.ncbi.nlm.nih.gov/pubmed/28455172
http://dx.doi.org/10.1016/j.vaccine.2017.04.041

Ejemplares similares